PetCaseFinder

Peer-reviewed veterinary case report

How fast Simparica and NexGard kill deer ticks on dogs

By Six, Robert H et al.·Published in Parasites & vectors·2016·Zoetis, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Comparative speed of kill of sarolaner (Simparica) and afoxolaner (NexGard against induced infestations of Ixodes scapularis on dogs.

Species:
dog

Plain-English summary

A group of dogs was treated with either sarolaner (Simparica) or afoxolaner (NexGard) to see which medication worked better against ticks that can spread Lyme disease. Within 24 hours, sarolaner showed over 99% effectiveness in killing ticks, while afoxolaner was less effective, dropping below 80% by the end of the study period. Sarolaner continued to provide strong protection against tick re-infestations for 35 days, with no side effects reported. This suggests that sarolaner is a reliable option for keeping dogs safe from ticks and the diseases they carry.

People also search for: dog tick prevention · Simparica vs NexGard · Lyme disease in dogs treatment

Abstract

BACKGROUND: The black-legged (or deer) tick, Ixodes scapularis, commonly infests dogs and cats in North America and is the main vector for the pathogen that causes Lyme disease in dogs and humans. The speed of kill of a parasiticide is critical to minimize the direct and deleterious effects of tick infestation and especially to reduce the risk of tick-borne pathogen transmission. In this study, speed of kill of a novel orally administered isoxazoline parasiticide, sarolaner chewable tablets (Simparica), against I. scapularis on dogs was evaluated and compared with afoxolaner (NexGard) for five weeks after a single oral dose. METHODS: Twenty four dogs were randomly allocated to treatment with either placebo, sarolaner (2 to 4 mg/kg), or afoxolaner (2.5 to 6.8 mg/kg) based on pretreatment tick counts. Dogs were examined and live ticks counted at 8, 12, and 24 h after treatment and subsequent re-infestations on Days 7, 14, 21, 28 and 35. Efficacy was determined at each time point relative to counts for placebo dogs. RESULTS: A single oral dose of sarolaner provided >99% efficacy within 24 h of treatment and >95% against subsequent weekly re-infestations of ticks consistently to Day 35. For the earlier time points, sarolaner significantly reduced tick counts versus placebo from Day 0 to Day 21 at 8 and 12 h, and on Day 35 at 12 h (P&#x2009;&#x2264;&#x2009;0.0174), while afoxolaner was only significantly lower at 8 h on Days 0 and 14 (P&#x2009;&#x2264;&#x2009;0.0309), and at 12 h on Day 0 only (P&#x2009;<&#x2009;0.0001). Significantly more live ticks were recovered from afoxolaner-treated dogs than from sarolaner-treated dogs at 24 h after infestation from Day 14 to Day 35 (P&#x2009;&#x2264;&#x2009;0.0278). At 24 h, efficacy (based on geometric mean counts) of afoxolaner declined to less than 80% from Day 21 through the end of the study, while efficacy for sarolaner was >95% for 35 days. There were no adverse reactions to treatments. CONCLUSIONS: In this controlled laboratory evaluation, sarolaner had a faster speed of kill against I. scapularis than afoxolaner. This was noticeably more pronounced towards the end of the monthly treatment period. The rapid and consistent kill of ticks provided by sarolaner within 24 h after a single oral dose and re-infestation over 35 days suggests this treatment will provide highly effective and reliable control of ticks over the entire treatment interval, and should reduce the risk of tick-borne diseases, including Lyme disease whose agent is vectored by I. scapularis.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26876891/